Exabis Library
Welcome to the e-CCO Library!
P0683: Is it time to move away from malnutrition screening as a gateway to a dietitian referral in patients with Inflammatory Bowel Disease? An investigation into nutritional Issues in Crohn’s Disease Remission
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0684: Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0685: Endoscopic severity at presentation and C-reactive protein predict immediate and twelve-month outcomes of second-line medical therapy in Acute Severe Ulcerative Colitis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0686: Steroid use in patients with inflammatory bowel disease – claims data indicate a decline in steroid use for the first time over a five-year observation period in Germany
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0687: Development and validation of a novel multimodal model based on histology of colonoscopic biopsy to predict primary non-response to infliximab in patients with Crohn's disease
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0688: Decisional conflict among patients with fistulizing perianal disease phenotype of Crohn’s disease at diagnosis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0689: A clinical study on the optimization of vedolizumab induction therapy for moderate to severe active Ulcerative Colitis at week 10
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P068: Aberrant brain function in active-stage ulcerative colitis patients: a resting-state functional MRI study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P068: Anti-fibrotic therapy for Crohn’s disease: in-vitro proof of concept with a selective ROCK2 inhibitor, LYC-53976, in the treatment of human intestinal myofibroblasts in stiffness and transforming growth factor β models
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P068: Discovery of IBD3540: A Novel Gut-Restricted Glutamate Carboxypeptidase II Inhibitor with Preclinical Anti-Colitis Activity
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P068: Evaluation of the therapeutic potential of metformin-pretreated tonsil-derived mesenchymal stem cells in a chronic colitis model
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P068: Loss of PTPN22 abrogates the beneficial effect of faecal microbiota transfer
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P068: Polyunsaturated fatty acid excess fuels pro-inflammatory transcriptional networks in GPX4 deficient intestinal epithelial cells
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P068: The combination of JAK1 and TPL2 or IRAK4 inhibitors is more effective than single agents in reducing TLR-mediated cytokine responses in human monocyte populations
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P069 CD73 promotes colitis-associated tumourigenesis in mice
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P0690: Purposeful design and integration of a pilot Inflammatory Bowel Disease (IBD) diet clinic into a multi-disciplinary IBD service demonstrates exemplar service utility and is of high value to patients
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0691: Impact of Ozanimod (OZA) on Circulating Neutrophils: Results from the Phase 3 Japanese True North (J-TN) Study of Patients (Pts) With Moderately to Severely Active Ulcerative Colitis (UC)
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0692: Comparing JAK inhibitors in ulcerative colitis: which one truly leads in the real world? Results from the ENEIDA registry of GETECCU
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0693: The Chicago Mesenteric Fat Index: A Novel Biomarker for Assessing Inflammation in Pediatric Crohn’s Disease with Point of Care Intestinal Ultrasound
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0694: Clinical response trajectories identify distinct subpopulations of ulcerative colitis patients and are linked to disease outcome across different therapy classes. Patient level analysis of 2378 participants from 6 randomized controlled trials in moderate-severe UC representing 8 different mechanisms of action.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM